Evidence map›Paper›PMID 34522596›Full record

ReviewActa pharmaceutica Sinica. B2021

Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies.

Sonal V Bhujbal, Biplob Mitra, Uday Jain, Yuchuan Gong, Anjali Agrawal, Shyam Karki, Lynne S Taylor, Sumit Kumar, Qi Tony Zhou

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

169 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

109 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sonal V BhujbalDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.
Biplob MitraOral Product Development, Bristol Myers Squibb, Summit, NJ 07901, USA.
Uday JainMaterial Science and Engineering, Bristol Myers Squibb, Summit, NJ 07901, USA.
Yuchuan GongOral Product Development, Bristol Myers Squibb, Summit, NJ 07901, USA.
Anjali AgrawalOral Product Development, Bristol Myers Squibb, Summit, NJ 07901, USA.
Shyam KarkiOral Product Development, Bristol Myers Squibb, Summit, NJ 07901, USA.
Lynne S TaylorDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.
Sumit KumarOral Product Development, Bristol Myers Squibb, Summit, NJ 07901, USA.
Qi Tony ZhouDepartment of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, USA.

Funding

Advancing innovative therapies against pandrug-resistant Gram-negative superbugsR01AI146160 · NIAID · PURDUE UNIVERSITY · PI LI, JIAN, ZHOU, QI · 2019 to 2023
$3.2M
Combating Deadly Gram-negative Lung Infections: An Inhalation and Systems ApproachR01AI132681 · NIAID · PURDUE UNIVERSITY · PI LI, JIAN, ZHOU, QI · 2017 to 2020
$2.4M
NIAID NIH HHS R01 AI132681NIAID NIH HHS R01 AI146160
6 · The paper itself

Abstract

Amorphous solid dispersions (ASDs) are popular for enhancing the solubility and bioavailability of poorly water-soluble drugs. Various approaches have been employed to produce ASDs and novel techniques are emerging. This review provides an updated overview of manufacturing techniques for preparing ASDs. As physical stability is a critical quality attribute for ASD, the impact of formulation, equipment, and process variables, together with the downstream processing on physical stability of ASDs have been discussed. Selection strategies are proposed to identify suitable manufacturing methods, which may aid in the development of ASDs with satisfactory physical stability.

Indexed as

3DP, three-dimensional printingAmorphous solid dispersionsASDs, amorphous solid dispersionsASES, aerosol solvent extraction systemCAP, cellulose acetate phthalateCO2, carbon dioxideCo-precipitationCSG, continuous-spray granulationDownstream processingDrug deliveryEPAS, evaporative aqueous solution precipitationEudragit®, polymethacrylates derivativesFDM, fused deposition modelingGAS, gas antisolventHME, hot-melt extrusionHPC, hydroxypropyl celluloseHPMCAS, hydroxypropyl methylcellulose acetate succinateHPMC, hydroxypropyl methylcelluloseHPMCP, hypromellose phthalateManufacturingMelting processPCA, precipitation with compressed fluid antisolventPGSS, precipitation from gas-saturated solutionsPLGA, poly(lactic-co-glycolic acidPVP, polyvinylpyrrolidonePVPVA, polyvinylpyrrolidone/vinyl acetateRESS, rapid expansion of a supercritical solutionSAS, supercritical antisolventscCO2, supercritical CO2SCFs, supercritical fluidsSEDS, solution-enhanced dispersion by SCFSelection criteriaSLS, selective laser sinteringSoluplus®, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymerSolvent evaporationStabilityTg, glass transition temperatureUSC, ultrasound compaction

Identifiers

PMID34522596
PMCPMC8424289

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.